Please ensure Javascript is enabled for purposes of website accessibility

What's the Outlook for Novavax Stock?

By Cory Renauer – Aug 31, 2020 at 8:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A coronavirus vaccine candidate in mid-stage studies could send shares of this biotech rocketing higher again.

Shares of Novavax (NVAX 0.60%) have retreated from their recent peaks, but this biotech stock is still up over 2,610% in 2020, and investors want to know if it can jump higher once again. 

On one hand, investors are right to be worried about the future of any 33-year-old vaccine developer that hasn't produced any successful vaccines yet. That said, governments around the world are supporting the development of Novavax's experimental coronavirus vaccine. 

A person peers through rolled-up U.S. currency as if looking through binoculars.

Image source: Getty Images.

Will shares of Novavax rocket higher again, or will the bottom fall out from under this risky biotech stock again?

Reasons to expect more gains

Instead of setting up shop in Cambridge, Massachusetts, or another global biotechnology hub, Novavax is headquartered in Gaithersburg, Maryland, next to the world's largest source of coronavirus vaccine funding. 

Novavax's contacts in Washington D.C. are proving invaluable. In July, the U.S. government awarded Novavax $1.6 billion to develop and deliver 100 million doses of NVX-CoV2373, a potential new coronavirus vaccine that recently began phase 2 clinical trials.

Most of the funding Novavax has received is committed to mass-produce this protein-based vaccine candidate before we know if it safely prevents SARS-CoV-2, the virus responsible for COVID-19 from spreading. Overall, the company has raised more than $2 billion to pay for manufacturing and a pivotal phase 3 study that could start before the end of the year. 

In addition to NVX-CoV2373, Novavax is also developing a next-generation flu vaccine. The company's NanoFlu program successfully completed a phase 3 study in March and Novavax could submit an application to the FDA before the end of the year.

Potential problems

At the beginning of 2020, Novavax was in a tight spot and boasted a tiny market cap of $129 million. Now that this is a $6.6 billion company, more gains like those experienced this summer will be a lot harder to come by. 

Phase 3 results that prove NVX-CoV2373 prevents the spread of COVID-19 could send Novavax shares rocketing higher, but investors need to consider the risks. So far we've seen relatively good phase 1 trial results, but they really don't tell us much. Less than 10% of new drug candidates that succeed in phase 1 eventually earn approval from the FDA. 

Bottles labeled covid 19 vaccine sit stop stacks of hundred dollar bills.

Image source: Getty Images.

At least two dozen coronavirus vaccine candidates are currently in clinical-stage development, and candidates from AstraZeneca (AZN 0.06%), Pfizer (PFE 0.73%), and Moderna (MRNA -0.58%) have already begun phase 3 trials that could produce interim results in the fall. Moderna's been developing drugs for a decade without a successful pivotal study under its belt, but AstraZeneca, Pfizer, and other pharma giants actually have loads of experience developing, and marketing successful vaccines.

Unfortunately, the closest Novavax came to success was an experimental respiratory syncytial virus vaccine candidate that showed some promise in a phase 2 trial but failed to reduce the risk of infection in larger phase 3 studies. If NVX-CoV2373 takes the same, well-worn path there won't be anything of significant value left in the company's late-stage pipeline.

This spring, NanoFlu hit predetermined goals in a phase 3 trial, but those goals didn't include actually lowering patients' risk of getting the flu. The safety and immune response data that Novavax has now will probably be sufficient to convince the FDA to approve its seasonal flu vaccine, but it's hard to see how Novavax will distinguish NanoFlu from competing vaccines marketed by competitors.

Frightening with a chance of sunshine

There is a slight chance that NVX-CoV2373 can outperform an increasing list of competing coronavirus vaccines but that doesn't make this stock worth the risk. If we find out later that NanoFlu is the only new vaccine candidate Novavax has a chance to launch in the foreseeable future, this stock will fall hard.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$16.64 (0.60%) $0.10
Pfizer Stock Quote
Pfizer
PFE
$49.57 (0.73%) $0.36
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.21 (0.06%) $0.04
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$175.38 (-0.58%) $-1.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.